Glenmark Share Price in Focus; Reports 35.1% YoY Revenue Growth in Q3 FY25

Glenmark Pharmaceuticals Limited announced its financial results for the third quarter ended December 31 2024.

On February 17, 2025, Glenmark share price opened at ₹1,320.00, down from its previous close of ₹1,323.05. At 9:55 AM, the share price of Glenmark was trading at ₹1,333.00, up by 0.75% on the NSE.

Q3 FY 2025 Financial Highlights

Glenmark Pharmaceuticals reported that consolidated revenue rose 35.1% YoY to ₹33,876 million from ₹25,067 million in Q3 FY24. The company’s EBITDA stood at ₹6,002 million, reflecting an EBITDA margin of 17.7%.

Profit After Tax (PAT) for the quarter was ₹3,480 million, with a PAT margin of 10.3%.

The company stated that in India, sales from the formulation business surged 300.2% YoY to ₹10,637 million from ₹2,658 million in the previous year. North America saw a modest 1.4% YoY growth in finished dosage formulations, reaching ₹7,813 million.

Revenue from the RoW (Asia, MEA, LATAM, and RCIS) segment grew 3% YoY to ₹7,491 million, though adverse currency movements in key markets impacted overall performance. Meanwhile, Glenmark’s Europe operations recorded a 14.8% YoY increase, with revenue rising to ₹7,297 million from ₹6,357 million in Q3 FY24.

Management Commentary

Commenting on the performance, the Chairman and Managing Director of Glenmark Pharmaceuticals Ltd, Glenn Saldanha, said, “We delivered strong and sustained growth this quarter, driven by robust performance across the regions. Our European business continued to perform well, while our branded markets demonstrated resilient growth. Strengthening our value-chain strategy, we secured MHRA authorization for WINLEVI® in the UK, marking a pivotal step in expanding our dermatology portfolio.”

He further added, “Looking ahead, we expect our North American business to gain momentum from FY26 onwards, supported by our growing respiratory and injectable portfolio. Additionally, we reached a significant milestone with IGI presenting promising first clinical data from our Phase 1 study of the trispecific TREAT™ antibody, ISB 2001, at the 66th American Society of Hematology (ASH) Annual Meeting. We continue to explore strategic partnerships to advance this asset.”

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd is a global, research-driven pharmaceutical company with a strong presence in the branded, generic, and OTC segments. It specialises in key therapeutic areas such as respiratory, dermatology, and oncology. With operations spanning over 80 countries, Glenmark operates 11 state-of-the-art manufacturing facilities across four continents.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.